Epicutaneous immunotherapy with a hypoallergenic Bet v 1 suppresses allergic asthma in a murine model

E-ISSN： 1398-9995|70|12|1559-1568

ISSN： 0105-4538

Source： ALLERGY, Vol.70, Iss.12, 2015-12, pp. : 1559-1568

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Mucosal Tolerance Induction with Hypoallergenic Molecules in a Murine Model of Allergic Asthma

International Archives of Allergy and Immunology, Vol. 124, Iss. 1-3, 2012-01 ,pp. : 391-394

Karger

Access to resources Recommend Favorite

Genetic Engineering of Recombinant Hypoallergenic Oligomers of the Major Birch Pollen Allergen, Bet v 1: Candidates for Specific Immunotherapy

International Archives of Allergy and Immunology, Vol. 118, Iss. 2-4, 1999-04 ,pp. : 218-219

Karger

Access to resources Recommend Favorite

Characterization of a Hypoallergenic Recombinant Bet v 1 Variant as a Candidate for Allergen-Specific Immunotherapy

International Archives of Allergy and Immunology, Vol. 145, Iss. 3, 2007-10 ,pp. : 193-206

Karger

Access to resources Recommend Favorite

Intranasal Treatment with a Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen Bet v 1 Prevents Allergic Sensitization and Airway Inflammation in Mice

International Archives of Allergy and Immunology, Vol. 126, Iss. 1, 2001-10 ,pp. : 68-77

Karger

Access to resources Recommend Favorite

Clinical Evaluation of Genetically Engineered Hypoallergenic rBet v 1 Derivatives

International Archives of Allergy and Immunology, Vol. 118, Iss. 2-4, 1999-04 ,pp. : 216-217

Karger

Access to resources Recommend Favorite